Consonance Capital

Consonance Capital is a healthcare investment firm based in New York City, established in 2005. The firm specializes in private equity investments, focusing on growth capital, leveraged buyouts, and recapitalizations, primarily within the lower middle market. Its investment strategy targets various segments of the healthcare sector, including payors, pharmaceutical companies, specialty distributors, and medical device manufacturers, emphasizing healthcare efficiency and innovation. Consonance Capital also engages in public equity investments through its management division, which operates collaboratively with its private equity branch. The firm typically invests between $20 million and $45 million in companies with revenues ranging from $25 million to $500 million, serving a diverse clientele that includes institutions and individual investors.

Mitchell Blutt

Co-Founder

Sean Breen

Partner

Manan Dadhania

Associate

Nancy-Ann DeParle

Partner

Edmands, Benjamin Bruce

Managing Partner and Co-Founder

Katherine Guan

Associate

Reza Keshavarz MD

Partner and Director of Therapeutics

Michael Lituchy

Senior Associate

Livingston CPA, CPA, Kevin Harold

Co-Founder, Partner, President, COO and Member of the Investment Committee

Eamon McCormick

Associate

Owen McDonough

Associate

Stephen McKenna

Managing Partner and Co-Founder

Mary Sobon

CFO

Soffer M.D., Benny

Co-Founder, Partner, Chief Investment Officer, Portfolio Manager and Member of Investment Committee

Javier Starkand

Partner

Peter Weinberg

Vice President

Michael Zhuang

Vice President

14 past transactions

Civic Eagle

Series A in 2022
Civic Eagle, Inc. is a software company that provides a workflow solution for advocates and policy teams, enabling them to discover, analyze, and manage state and federal legislation. Founded in 2015 and based in Minnesota, Civic Eagle offers a platform called Enview that consolidates legislative information and team communications, allowing lobbyists and policy professionals to streamline their efforts without manual data entry. The platform helps users track and engage with legislation across the country, empowering policy advocates to focus on their campaigns and promote more effective democratic outcomes for their communities.

Surrozen

Post in 2021
Surrozen, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, focused on developing targeted regenerative antibodies to repair damaged tissues and improve organ function. The company utilizes antibody platforms that act as Wnt and R-spondin mimetics to stimulate tissue regeneration in a variety of organs. Its key programs include SZN-043, which aims to promote hepatocyte regeneration in liver diseases, and SZN-1326, designed to repair diseased epithelial tissue for patients with inflammatory bowel disease. Surrozen's research targets several disease areas, including conditions affecting the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system, by engaging the body’s natural biological repair mechanisms. The company was incorporated in 2015 and continues to advance its innovative therapeutic approaches.

Rivy

Pre Seed Round in 2021
Rivy is making it easier to finance small and medium sized businesses in Africa. There is a need for financing of $158 bn for SMEs in Nigeria alone. To start, Rivy o helps SMEs access and spend lender capital effectively. During their first full operational year in 2020, the Rivy o co--founders leveraged their domain expertise and founding experience to beat their 2020 goal by 50%.
Silence Therapeutics is a biotechnology company based in London, focused on the discovery, development, and delivery of innovative RNA therapeutics for various medical conditions, including hematology, cardiovascular diseases, and rare metabolic disorders. The company specializes in designing short interfering RNA (siRNA) molecules that activate the RNA interference (RNAi) pathway to selectively degrade target messenger RNAs. Its product pipeline includes SLN124, aimed at treating iron overload disorders, SLN360, which targets cardiovascular diseases associated with elevated lipoprotein levels, and SLN500 for complement-mediated diseases. Silence Therapeutics has established strategic collaborations with AstraZeneca to develop small interfering RNA therapeutics for a range of diseases, and with Genomics England Limited. The company was previously known as SR Pharma before rebranding in 2007.
Mersana Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of antibody-drug conjugates (ADCs) for cancer treatment. The company utilizes its proprietary biodegradable polymer platform, Dolaflexin, to create a pipeline of ADC product candidates aimed at addressing oncology indications with significant unmet needs. Its lead candidate, XMT-1536, is currently in Phase I clinical trials targeting NaPi2b for the treatment of ovarian cancer, non-small cell lung cancer, and other rare conditions. Mersana is also advancing additional candidates, including XMT-1660, targeting B7-H4, and XMT-2056, a STING agonist ADC, both designed to improve tolerability and therapeutic outcomes. The company has established strategic partnerships with Merck KGaA and Asana BioSciences to further develop its ADC candidates. Founded in 2005, Mersana Therapeutics aims to deliver innovative treatments to patients through its advanced research and development efforts.

Orsini Healthcare

Acquisition in 2019
Orsini Healthcare manages the handling and service requirements of pharmaceuticals including dispensing, distribution, reimbursement, case management, and other services to patients with chronic diseases. They help patients, doctors, insurance companies, and manufacturers improve care, processes, and outcomes.

Psychiatric Medical Care

Acquisition in 2018
Psychiatric Medical Care, LLC is a Nashville-based company that specializes in behavioral health management services, primarily focusing on the geriatric population. Founded in 2003, the company provides a range of services including outpatient programs, telepsychiatry, and intensive outpatient care for adults facing mental health issues such as depression, anxiety, mood disorders, and post-traumatic stress disorder. In addition to direct patient care, Psychiatric Medical Care supports hospitals and partners by offering recruitment, training, and educational resources for clinical functions. The organization is dedicated to enhancing the quality of life for its patients through comprehensive mental health treatment and ongoing support.

Bako Diagnostics

Private Equity Round in 2016
Bako Diagnostics is a healthcare services company that provides diagnostic and therapeutic services. They specialise in anatomic pathology, nail DNA testing, ENFD, bacteriology, and mycology. They are committed to the advancement of podiatric dermatology through education, research, and financial support that no other national lab or pathology group can match.

Bako Diagnostics

Acquisition in 2016
Bako Integrated Physician Solutions is the premier provider of diagnostic and therapeutic services focusing on the skin, soft tissue and bone of the lower extremity. Their pathology team provides not just information, but also intelligence to enable better patient care.

Telesta Therapeutics

Venture Round in 2015
Telesta Therapeutics is a Canadian biopharmaceutical company dedicated to the development, manufacturing, and commercialization of innovative therapeutics aimed at addressing significant unmet medical needs, primarily in oncology. The company is focused on creating novel medicines that can transform the treatment landscape for serious diseases, including cancer and immune disorders. Its lead product, MCNA, has successfully completed a Phase III pivotal study for patients with non-muscle invasive bladder cancer who have not responded to initial treatment with bacillus Calmette-Guérin (BCG). Telesta submitted a Biologics Licensing Application to the U.S. FDA in June 2015 and aims to provide MCNA to patients and healthcare providers pending approval. Ultimately, the company seeks to enhance the quality of life and extend survival for individuals affected by bladder cancer, one of the most prevalent cancers today.

Enclara Pharmacia

Acquisition in 2014
Enclara Pharmacia, Inc. is a comprehensive provider of medications and clinical services tailored specifically for the hospice and palliative care sectors. Founded in 1996 and based in Philadelphia, the company offers a range of solutions, including mail order pharmacy services, clinical support, business intelligence tools, and educational resources. Enclara Pharmacia utilizes both a direct-to-patient mail order model and a network of retail pharmacies to ensure efficient medication delivery to patients in their homes. The company focuses on improving patient experiences and operational efficiencies for hospice providers across the United States. As a subsidiary of Eagle RX, Inc., Enclara Pharmacia emphasizes value-based care, leveraging its expertise and technology to enhance the quality of life for individuals facing progressive illnesses.

Kepro

Acquisition in 2014
Kepro is a provider of technology-enabled services focused on helping individuals remain in their communities through effective care coordination and quality assurance. The company offers a range of solutions, including care management, assessments, enrollment, specialty case management, and pharmacy management. Additionally, Kepro specializes in utilization management, maternity management, and independent medical reviews, catering primarily to federal healthcare payers and select self-funded organizations. Their services are designed to enhance healthcare quality, improve operational accuracy, and increase overall efficiency for their clients. Kepro also provides reporting and analytic services to further support the operational needs of these organizations.

Enclara Pharmacia

Private Equity Round in 2014
Enclara Pharmacia, Inc. is a comprehensive provider of medications and clinical services tailored specifically for the hospice and palliative care sectors. Founded in 1996 and based in Philadelphia, the company offers a range of solutions, including mail order pharmacy services, clinical support, business intelligence tools, and educational resources. Enclara Pharmacia utilizes both a direct-to-patient mail order model and a network of retail pharmacies to ensure efficient medication delivery to patients in their homes. The company focuses on improving patient experiences and operational efficiencies for hospice providers across the United States. As a subsidiary of Eagle RX, Inc., Enclara Pharmacia emphasizes value-based care, leveraging its expertise and technology to enhance the quality of life for individuals facing progressive illnesses.

Corindus

Series B in 2008
Corindus designs, manufactures, and commercializes remote robotic systems for interventional procedures. The company's products include CorPath, which enables physicians to perform catheterization procedures from a remote location away from the radiation zone. The company was formerly known as Navicath, Ltd. Corindus was founded in 2002 and is based in Waltham, Massachusetts.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.